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Potential of vascular endothelial growth factor as a biomarker of coronary artery
disease in subjects undergoing CABG surgery
Teaka Jackson1,2, Sarah M. Peterson3, Amanda J. Favreau-Lessard1, Joanne Burgess4, Susan Bosworth-Farrell4,
Robert S. Kramer1,4, Sergey Ryzhov1, Douglas B. Sawyer1,4, Michael P. Robich1,4
Introduction

Due to local hypoxic conditions during surgery, we hypothesize that circulating VEGF levels
increase immediately following CABG surgery. However, at time points following surgery, we expect
a decrease in VEGF, indicating successful revascularization.
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Absorbance

Undetectable

16

50

Age*

66 ± 10

63 ± 11

Female†

5 (31%)

20 (40%)

p‐value

0.47‡
0.57§

Male†

11 (69%)

30 (60%)

BMI*

32.3 ± 7.5

29.6 ± 5.8

0.18‡

82 ± 30

85 ± 28

1500

CPB time (min)*

100 ± 34

105 ± 35

0.55‡
0.60‡

Smoking history†

8 (50%)

36 (72%)

0.13§

HbA1c %*

7.0 ± 1.9

6.7 ± 1.8

0.67‡

EF<50%†

2 (13%)

12 (24%)

0.49§

400

Undetectable;
Assigned 15.6 pg/mL

200

*mean ± SD, †number of research subjects (%), BMI=body mass index, CPB=cardiopulmonary
bypass, HbA1c=hemoglobin A1c, EF=ejection fraction
‡Mann‐Whitney t‐test, §Fisher exact test

Conclusions
Preop

Figure 1. Determining concentration of VEGF in
plasma samples
Left Representative VEGF ELISA plate. Lane 1
contains standard concentrations, and lanes 2 through
6 contain subject plasma samples
Right Standards were plotted in GraphPad Prism and
plasma VEGF concentrations were back-calculated
based on the calibration curve

Figure 2. Subject expression of VEGF at preoperative time point
The majority of patients (69.7%) did not have detectable
levels of VEGF at any time point (red). VEGF protein was
characterized by interindividual variability (CQD=34%).
Therefore, subjects with detectable levels of VEGF at the
pre-operative time point (black) were considered VEGF
expressors and subjected to further statistical analysis.

• Plasma levels of VEGF are characterized by
interindividual variability
• Individual VEGF expression appears to vary
in response to CABG surgery
• CABG surgery did not induce changes in the
level of circulating VEGF, limiting its potential
use as a biomarker of cardiometabolic stress
in CABG patients

Future Directions
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• Determine Hypoxic Inducible Factor 1 (a
transcription factor for VEGF) expression by ELISA
• Investigate the biological activity of VEGF in CAD
patients
• Examine potential relationships with cytokine, and
clinical data and outcomes
• Understand if patient subpopulations (diabetes,
heart failure) have varying VEGF levels and if they
are impacted clinically

Figure 3. VEGF levels do not differ between time
points analyzed
VEGF expression for the 16 subjects with detectable
VEGF levels was subjected to Friedman’s test and Dunn’s
multiple comparisons test to determine statistical
significance. Analysis incorporated 11 subjects due to
missing data at one or more time points for n=5 subjects.
We did not observe any significant changes in VEGF
expression across the five time points tested.
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Methods
• Research was performed in accordance with study
protocols approved by Maine Medical Center
Institutional Review Board
• The study cohort consisted of plasma samples
from 73 patients undergoing CABG surgery at
Maine Medical Center (MMC) in Portland, ME
• Plasma samples were collected prior to operation
(pre-op), during surgery, and 4-8, 24 and 96 hours
following surgery
• VEGF concentration was determined using a
DuoSet enzyme-linked immunosorbent assay
(ELISA) kit (R&D Systems, sensitivity range
31.3-2000 pg/mL)
• Undetectable levels of VEGF (<31.3 pg/mL) were
assigned a concentration equal to one-half of the
lowest calibration point (15.6 pg/mL)
• All statistical analyses were performed in
GraphPad Prism and a p-value <0.05 was
considered statistically significant

Table 1. Demographic data of VEGF
expressors is not significantly different from
those with undetectable levels

Number of subjects

48

• Coronary artery disease (CAD) causes local
hypoxia due to reduced blood flow
• Hypoxic conditions are known to induce vascular
endothelial growth factor (VEGF) production, a key
contributor to angiogenesis
• The purpose of this study was to determine the
potential of VEGF as a marker of myocardial
stress in subjects with CAD undergoing coronary
artery bypass grafting (CABG) surgery

Hypothesis

Figure 4. Representative data demonstrating
different changes in VEGF expression following
surgery
VEGF expression in response to CABG surgery differed
within the study cohort. Although some individuals
showed no changes following surgery, others were
characterized by dynamic changes in VEGF expression.
These changes included a decrease, an increase, or an
increase followed by a decrease in VEGF expression.
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